This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome

This study has been completed.
Information provided by (Responsible Party):
Afferent Pharmaceuticals, Inc. Identifier:
First received: March 30, 2012
Last updated: April 14, 2017
Last verified: April 2017
The purpose of this study is to assess the efficacy of a single dose level of gefapixant (AF-219/MK-7264) in female subjects with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of treatment.

Condition Intervention Phase
Bladder Pain Syndrome Drug: Gefapixant Drug: Sugar Pill Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Afferent Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • The Primary Efficacy Endpoint of This Study is Change in the 'Average Pain' NPRS Score. [ Time Frame: Baseline and 4 Weeks ]
    Subjects were instructed to select a number on a scale that best described the severity of bladder pain during the past 24 hours. The scale was between 0 and 10 where 0 was no pain and 10 was the worst pain possible. The scale was completed by telephone (an interactive voice response system[IVRS]) every evening at bedtime.

Secondary Outcome Measures:
  • Painful Bladder/Interstitial Cystitis Symptom Diary (PBIC-SD) [ Time Frame: Baseline and 4 Weeks ]
    The PBIC-SD was an 8-item subject self-report measure for assessing the severity of bladder pain syndrome. All items were graded on a scale from 0 (good condition) to 4 (poor condition) for a total score between 0 and 32.

  • O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) [ Time Frame: Baseline and 4 Weeks ]
    The ICSI contains 4 items that measured how problematic symptoms were for subjects with bladder pain syndrome. Each question in the ICPI was on a scale of 0-4, where each answer was given a specific rating. The sum of the item scores indicated more problematic symptoms. The index score ranged from 0-16 where higher scores indicated more problematic symptoms.

  • Genitourinary Pain Index (GUPI) [ Time Frame: Baseline and 4 Weeks ]
    The GUPI is an instrument that is used to assess the degree of symptoms in women with genitourinary pain complaints. The sum of the items yields three subscales and a total score. The subscales are pain (0-23), urinary (0-10), and quality of life (0-12). The sum of the subscales is the total score (0-45). Higher scores indicate more severe symptoms.

Enrollment: 74
Actual Study Start Date: March 31, 2012
Study Completion Date: May 31, 2014
Primary Completion Date: May 31, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gefapixant Drug: Gefapixant
Other Names:
  • AF-219
  • MK-7264
Placebo Comparator: Sugar Pill Drug: Sugar Pill

Detailed Description:
This study is a double-blind, placebo-controlled, randomized trial designed to assess the efficacy and safety of a single dose level of gefapixant in female subjects with moderate to severe IC/BPS. The study will consist of 4 phases: Screening, Baseline, Treatment, and Follow-up.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women
  • Women of child bearing potential must not be pregnant during the study and must use two forms of birth control
  • Clinical evidence of IC/BPS
  • Have provided written informed consent

Exclusion Criteria:

  • History of diseases that can be confused for IC/BPS
  • Unable to void spontaneously
  • Immunosuppressant, intravesicular, nerve stimulator or opioid treatment during the study and for certain periods prior to start of the study.
  • Changes to doses of Elmiron®, antidepressant, alpha-adrenergic antagonist, H1 antagonist, or anti-muscarinic treatment within a certain period prior to the start of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01569438

  Show 42 Study Locations
Sponsors and Collaborators
Afferent Pharmaceuticals, Inc.
  More Information

Responsible Party: Afferent Pharmaceuticals, Inc. Identifier: NCT01569438     History of Changes
Other Study ID Numbers: 7264-005
AF219-005 ( Other Identifier: Afferent Pharmaceuticals )
Study First Received: March 30, 2012
Results First Received: September 23, 2016
Last Updated: April 14, 2017

Additional relevant MeSH terms:
Cystitis, Interstitial
Pathologic Processes
Urinary Bladder Diseases
Urologic Diseases processed this record on August 18, 2017